Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New patent reform bill

Executive Summary

Sen. Jon Kyl, R-Ariz., plans to introduce a patent damages bill that does not include the apportionment provisions opposed by drug lobbyists and contained in legislation sponsored by Sen. Patrick Leahy, D-Vt. (S. 1145). The House and Senate Judiciary Committees each approved versions of Leahy's bill in July 2007, but the bill has since stalled (1"The Pink Sheet," July 23, 2007, p. 20). Leahy's bill would require courts to select one of several methods of calculating royalties. Kyl's legislation, which the senator plans to introduce in September, would codify the so-called "Georgia-Pacific factors": 15 factors for calculating royalty payments for patents, established in a 1970 federal court case...

You may also be interested in...

Patent Reform Bills Clear House And Senate Judiciary Committees

The House and Senate Judiciary Committees each approved versions of patent reform legislation the week of June 16 that respond to some concerns raised by drug and medical device lobbyists, but that still leave industry unsatisfied and primed to seek changes before the bills go to a floor vote

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts